Jeffrey S. Parkin

Array ( [id] => 11480491 [patent_doc_number] => 09587022 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-07 [patent_title] => 'Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity' [patent_app_type] => utility [patent_app_number] => 14/133256 [patent_app_country] => US [patent_app_date] => 2013-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 8314 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14133256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9737212 [patent_doc_number] => 20140272930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'Compositions And Methods For Determining Resistance To Inhibitors Of Virus Entry Using Recombinant Virus Assays' [patent_app_type] => utility [patent_app_number] => 14/100467 [patent_app_country] => US [patent_app_date] => 2013-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 18922 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14100467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12143765 [patent_doc_number] => 09878001 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-30 [patent_title] => 'Immunosuppressive Tat derivative polypeptides' [patent_app_type] => utility [patent_app_number] => 14/099475 [patent_app_country] => US [patent_app_date] => 2013-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 30 [patent_no_of_words] => 21215 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14099475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11749290 [patent_doc_number] => 09707287 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-18 [patent_title] => 'Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein' [patent_app_type] => utility [patent_app_number] => 14/096424 [patent_app_country] => US [patent_app_date] => 2013-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 53921 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14096424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11749290 [patent_doc_number] => 09707287 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-18 [patent_title] => 'Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein' [patent_app_type] => utility [patent_app_number] => 14/096424 [patent_app_country] => US [patent_app_date] => 2013-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 53921 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14096424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10414258 [patent_doc_number] => 20150299268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-22 [patent_title] => 'HIV-1 ENV-BINDING ANTIBODIES, FUSION PROTEINS, AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/649565 [patent_app_country] => US [patent_app_date] => 2013-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13960 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14649565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9512094 [patent_doc_number] => 20140148586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-29 [patent_title] => 'DESIGNING A SOLUBLE FULL-LENGTH HIV-1 GP41 TRIMER' [patent_app_type] => utility [patent_app_number] => 14/091401 [patent_app_country] => US [patent_app_date] => 2013-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 12091 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14091401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9396122 [patent_doc_number] => 20140093528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-03 [patent_title] => 'DELETION OF THE BETA 20-21 LOOP IN HIV GP120 EXPOSES THE CD4 BINDING SITE FOR IMPROVED ANTIBODY BINDING AND ANTIBODY INDUCTION' [patent_app_type] => utility [patent_app_number] => 14/089460 [patent_app_country] => US [patent_app_date] => 2013-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 30132 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14089460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9338398 [patent_doc_number] => 20140065180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-06 [patent_title] => 'WEST NILE VIRUS VACCINE, AND METHOD FOR PRODUCTION THEREOF' [patent_app_type] => utility [patent_app_number] => 14/070948 [patent_app_country] => US [patent_app_date] => 2013-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9365 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14070948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11843456 [patent_doc_number] => 09730996 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins' [patent_app_type] => utility [patent_app_number] => 14/062125 [patent_app_country] => US [patent_app_date] => 2013-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 11345 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14062125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9306101 [patent_doc_number] => 20140044776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-13 [patent_title] => 'SERPIN DRUGS FOR TREATMENT OF VIRAL INFECTION AND METHOD OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/058808 [patent_app_country] => US [patent_app_date] => 2013-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 19327 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14058808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13051529 [patent_doc_number] => 10047146 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-14 [patent_title] => Broadly-neutralizing anti-HIV antibodies [patent_app_type] => utility [patent_app_number] => 14/436608 [patent_app_country] => US [patent_app_date] => 2013-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 16 [patent_no_of_words] => 30251 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14436608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9435045 [patent_doc_number] => 20140112952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-24 [patent_title] => 'ATTENUATED POLIOVIRUSES' [patent_app_type] => utility [patent_app_number] => 14/053426 [patent_app_country] => US [patent_app_date] => 2013-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 5972 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14053426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9512089 [patent_doc_number] => 20140148582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-29 [patent_title] => 'NUCLEIC ACIDS ENCODING BIOLOGICALLY ACTIVE POLYPEPTIDES DERIVED FROM A NOVEL EARLY STAGE PREGNANCY FACTOR DESIGNATED MATERNIN (MA)' [patent_app_type] => utility [patent_app_number] => 14/051816 [patent_app_country] => US [patent_app_date] => 2013-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 58138 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14051816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10613827 [patent_doc_number] => 09333255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-10 [patent_title] => 'Methods of enhancing antibody-based antiviral therapies by administering KIR2DL-binding antibodies' [patent_app_type] => utility [patent_app_number] => 14/043402 [patent_app_country] => US [patent_app_date] => 2013-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15642 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14043402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9396103 [patent_doc_number] => 20140093509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-03 [patent_title] => 'Screening Method for the Identification of Agents Capable of Activating CD4+CD25+ Regulatory T-Cells Through Interactions with the HIV-1 GP120 Binding Site on CD4' [patent_app_type] => utility [patent_app_number] => 14/031919 [patent_app_country] => US [patent_app_date] => 2013-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17566 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14031919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9205004 [patent_doc_number] => 20140004181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-02 [patent_title] => 'COMPOSITIONS AND METHODS FOR EXOSOME TARGETED EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/019601 [patent_app_country] => US [patent_app_date] => 2013-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14975 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14019601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9205004 [patent_doc_number] => 20140004181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-02 [patent_title] => 'COMPOSITIONS AND METHODS FOR EXOSOME TARGETED EXPRESSION' [patent_app_type] => utility [patent_app_number] => 14/019601 [patent_app_country] => US [patent_app_date] => 2013-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14975 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14019601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12305877 [patent_doc_number] => 09938325 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-10 [patent_title] => HIV-1 antigens with discrete conformational forms in the V1/V2 domain and methods of use thereof [patent_app_type] => utility [patent_app_number] => 14/426646 [patent_app_country] => US [patent_app_date] => 2013-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 15 [patent_no_of_words] => 7603 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14426646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9121999 [patent_doc_number] => 20130288922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-31 [patent_title] => 'ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE' [patent_app_type] => utility [patent_app_number] => 13/940011 [patent_app_country] => US [patent_app_date] => 2013-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 13979 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13940011 [rel_patent_id] =>[rel_patent_doc_number] =>)